BioReference initiates COVID-19 testing for all National Basketball Association players and referees, as well as team and league staff for its season restart in Orlando on July 30
ELMWOOD PARK, N.J., 13 de julio de 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), will provide COVID-19 testing oversight for the National Basketball Association’s (NBA) players and referees, as well as team and league staff participating in the NBA’s season restart in Orlando.
Under the agreement with the NBA, BioReference will provide COVID-19 testing, which includes PCR diagnostics, rapid diagnostics and antibody testing.
The NBA and BioReference collaborated on testing protocols to provide the safest possible environment to restart the 2019-20 NBA season, going to extraordinary lengths to understand both the threats of the virus and the best means to control its spread. Testing protocols were established in consultation with infectious disease experts to ensure the safety of players and employees.
“Collaborating with the National Basketball Association throughout the COVID-19 pandemic has been a privilege for BioReference,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “The extensive, detailed and systematic protocols put in place by the NBA leadership highlights the priority they are placing on the overall safety of the NBA players, referees and other team and league staff, as well as their families. Similar to testing for employers trying to get their employees back to work, professional sports entertainment is another integral part of the everyday American experience. We are proud to be part of the solution that can help the nation return to normal.”
Para obtener más información, visite https://www.bioreference.com/coronavirus/employers-and-government-authorities/.
Información acerca de BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. BioReference has been working expeditiously to develop and offer test services that will yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists. With a leading position in the areas of genetics, women’s health, maternal fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. For more information, visit www.bioreference.com.
Información acerca de OPKO Health, Inc.
OPKO es una compañía biofarmacéutica y de diagnóstico multinacional que busca posicionarse como líder de la industria en grandes mercados de rápido crecimiento, a través de sus tecnologías exclusivas y su experiencia e innovación en el descubrimiento, el desarrollo y la comercialización. Para obtener más información, visite www.opko.com.
Advertencia respecto de declaraciones con perspectivas de futuro
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding BioReference’s antibody screening test, the availability of the test and the role and value of the information provided and its impact on decisions relative to the safety of employees and customers, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Muchos factores podrían hacer que nuestras actividades o resultados reales difieran sustancialmente de las actividades y resultados anticipados en las declaraciones con perspectivas de futuro. Estos factores incluyen aquellos descritos en los informes anuales de OPKO Health, Inc. los informes anuales del formulario 10-K de OPKO Health, Inc. presentados y a presentarse ante la Comisión de Bolsa y Valores y en otras presentaciones nuestras ante la Comisión de Bolsa y Valores. Además, las declaraciones con perspectivas de futuro también pueden verse afectadas de manera adversa por factores generales del mercado, desarrollo de productos de la competencia, disponibilidad de productos, normas y leyes federales y estatales, el proceso regulatorio de nuevos productos e indicaciones, problemas de fabricación que puedan surgir, posiciones de patentes y litigios, entre otros factores. Las proyecciones que contiene este comunicado de prensa solo expresan la situación a la fecha en que se realizaron, y no asumimos obligación alguna de actualizar las proyecciones. Tenemos la intención de que todas las declaraciones con perspectivas de futuro estén sujetas a las disposiciones de puerto seguro de la ley PSLRA.
Contacto de BioReference Laboratories para los medios:
Hillary Titus, htitus@bioreference.com